INDICATION & USAGE

IXIARO is a vaccine indicated for the prevention of disease caused by Japanese encephalitis virus, approved for use in individuals 2 months of age and older.

Important Safety Information

Severe allergic reaction after a previous dose of IXIARO, any other Japanese encephalitis vaccine,  or any component of IXIARO, including protamine sulfate a compound known to cause hypersensitivity reactions in some individuals is a contraindication to administration of IXIARO.  Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO is considered.

Vaccination with IXIARO may not protect all individuals.  Individuals with a weakened immune system may have a diminished immune response to IXIARO.  Fainting may occur when receiving any injection, including IXIARO.  Tell your healthcare practitioner if you have a history of fainting from injections.

The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, muscle pain, and injection site pain and tenderness in adults.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.  You should ask your healthcare practitioner for medical advice about adverse events.

For more information, please see the physician’s Prescribing Information and ask your healthcare practitioner about the risk and benefits of IXIARO.

    

INDICATION & USAGE

IXIARO is a vaccine indicated for the prevention of disease caused by Japanese encephalitis virus, approved for use in individuals 2 months of age and older.

Important Safety Information

Severe allergic reaction after a previous dose of IXIARO, any other Japanese encephalitis vaccine,  or any component of IXIARO, including protamine sulfate  a compound known to cause hypersensitivity reactions in some individuals  is a contraindication to administration of IXIARO.  Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO is considered.

Vaccination with IXIARO may not protect all individuals.  Individuals with a weakened immune system may have a diminished immune response to IXIARO.  Fainting may occur when receiving any injection, including IXIARO.  Tell your healthcare practitioner if you have a history of fainting from injections.

The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, muscle pain, and injection site pain and tenderness in adults.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.  You should ask your healthcare practitioner for medical advice about adverse events.

For more information, please see the physician’s Prescribing Information and ask your healthcare practitioner about the risk and benefits of IXIARO.

    

 

 

One vaccine can help protect you4

IXIARO® is a vaccine indicated for the prevention of disease caused by Japanese encephalitis (JE) virus 
for people 2 months of age and older.12

IXIARO® is a vaccine indicated for the prevention of disease caused by Japanese encephalitis (JE) virus 
for people 2 months of age and older.12

IXIARO® has a well-established safety profile
and protective immune response.
12

Immune Response Kinetics After Primary Immunization12

Protect Against JE With Vaccination8,9

  • The safety of IXIARO® has been confirmed in multiple clinical studies12
  • IXIARO® has been used across Europe and the US since 20094
  • Common adverse reactions include fever, irritability, diarrhea, and injection site redness in those up to 1 year of age; fever in children up to age 12; and pain and tenderness in adolescents. In adults the most common side effects are headache, muscle pain, and injection site pain and tenderness12

IXIARO® Vaccination Schedule

  • For adults aged 18 – 65 years, the vaccine is given in 2 doses, 7 days apart (accelerated schedule) or 28 days apart (standard schedule), and vaccination should be completed 7 days before departure12
  • For pediatric (2 months to <18 years) and older adult (66+ years) travelers, the vaccine is given in 2 doses, 28 days apart (standard schedule), and vaccination should be completed 7 days before departure12
  • A booster dose (third dose)* may be given at least 11 months after completion of the primary immunization series if ongoing exposure or re-exposure to JE virus is expected12

*Children from 14 months to <3 years of age should receive a single 0.25 mL booster dose. Individuals 3 years of age and older should receive a single 0.5 mL booster dose.

Vaccination & Travel Timeline12

For travelers preparing a trip to Asia

IXIARO® is provided as suspension for injection in a single-dose, prefilled syringe.

Ask your healthcare professional about
the risks and benefits of IXIARO®

Ask your healthcare professional about
the risks and benefits of IXIARO®

Indication & Usage

IXIARO is a vaccine indicated for the prevention of disease caused by Japanese encephalitis virus, approved for use in individuals 2 months of age and older.

Important Safety Information

Severe allergic reaction after a previous dose of IXIARO, any other Japanese encephalitis vaccine,  or any component of IXIARO,  including protamine sulfate a compound known to cause hypersensitivity reactions in some individuals is a contraindication to administration of IXIARO.  Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO is considered.

Vaccination with IXIARO may not protect all individuals.  Individuals with a weakened immune system may have a diminished immune response to IXIARO.  Fainting may occur when receiving any injection, including IXIARO.  Tell your healthcare practitioner if you have a history of fainting from injections.

The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, muscle pain, and injection site pain and tenderness in adults.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.  You should ask your healthcare practitioner for medical advice about adverse events.

For more information, please see the physician’s Prescribing Information and ask your healthcare practitioner about the risk and benefits of IXIARO.

 

 

 

Site is intended for travelers from the United States

1807-US-IX-044-1018 | 10/18 | Copyright © 2018 Valneva USA, Inc. All Rights Reserved.